Crinetics Pharmaceuticals, Inc.
CRNX
$30.93
$0.842.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.51% | -61.50% | -74.11% | -78.00% | -71.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.51% | -61.50% | -74.11% | -78.00% | -71.35% |
| Cost of Revenue | 41.20% | 17.89% | 14.70% | 7.74% | 4.16% |
| Gross Profit | -41.57% | -18.75% | -16.87% | -10.35% | -6.71% |
| SG&A Expenses | 78.25% | 71.48% | 71.68% | 69.51% | 60.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.95% | 50.92% | 49.98% | 45.04% | 41.92% |
| Operating Income | -52.21% | -51.81% | -52.22% | -47.84% | -44.78% |
| Income Before Tax | -43.05% | -39.41% | -39.10% | -39.36% | -40.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.05% | -39.41% | -39.10% | -39.36% | -40.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.05% | -39.41% | -39.10% | -39.36% | -40.59% |
| EBIT | -52.21% | -51.81% | -52.22% | -47.84% | -44.78% |
| EBITDA | -51.93% | -51.29% | -51.72% | -47.54% | -44.68% |
| EPS Basic | -9.10% | -1.20% | -0.12% | -2.14% | -10.61% |
| Normalized Basic EPS | -9.09% | -1.20% | -0.11% | -2.14% | -10.62% |
| EPS Diluted | -9.10% | -1.20% | -0.12% | -2.14% | -10.61% |
| Normalized Diluted EPS | -9.09% | -1.20% | -0.11% | -2.14% | -10.62% |
| Average Basic Shares Outstanding | 30.24% | 37.19% | 39.09% | 36.42% | 27.56% |
| Average Diluted Shares Outstanding | 30.24% | 37.19% | 39.09% | 36.42% | 27.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |